NASDAQ:NMRA Neumora Therapeutics (NMRA) Stock Price, News & Analysis $1.49 -0.03 (-1.97%) Closing price 03/7/2025 04:00 PM EasternExtended Trading$1.48 -0.01 (-0.74%) As of 03/7/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Neumora Therapeutics Stock (NASDAQ:NMRA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Neumora Therapeutics alerts:Sign Up Key Stats Today's Range$1.30▼$1.4950-Day Range$1.41▼$11.0652-Week Range$1.30▼$21.00Volume1.40 million shsAverage Volume1.42 million shsMarket Capitalization$240.73 millionP/E RatioN/ADividend YieldN/APrice Target$10.14Consensus RatingModerate Buy Company OverviewNeumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.Read More… Remove Ads Neumora Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks72nd Percentile Overall ScoreNMRA MarketRank™: Neumora Therapeutics scored higher than 72% of companies evaluated by MarketBeat, and ranked 275th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingNeumora Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageNeumora Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Neumora Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neumora Therapeutics are expected to grow in the coming year, from ($1.61) to ($1.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neumora Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neumora Therapeutics is -0.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeumora Therapeutics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Neumora Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.05% of the float of Neumora Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeumora Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neumora Therapeutics has recently increased by 9.16%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeumora Therapeutics does not currently pay a dividend.Dividend GrowthNeumora Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted20.05% of the float of Neumora Therapeutics has been sold short.Short Interest Ratio / Days to CoverNeumora Therapeutics has a short interest ratio ("days to cover") of 3.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neumora Therapeutics has recently increased by 9.16%, indicating that investor sentiment is decreasing significantly. News and Social Media1.7 / 5News Sentiment0.14 News SentimentNeumora Therapeutics has a news sentiment score of 0.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 65 news articles for Neumora Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 8 people have searched for NMRA on MarketBeat in the last 30 days. This is a decrease of -27% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Neumora Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neumora Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,783.00 in company stock.Percentage Held by Insiders26.40% of the stock of Neumora Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions47.65% of the stock of Neumora Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neumora Therapeutics' insider trading history. Receive NMRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neumora Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NMRA Stock News HeadlinesJoshua Pinto Sells 8,048 Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) StockFebruary 21, 2025 | insidertrades.comStifel Downgrades Neumora Therapeutics (NMRA)March 8 at 2:11 AM | msn.comFort Knox Truth Bomb—Gold Set to SkyrocketOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s already performing nearly twice as well as gold this year and looks ready to go much higher. If you wait for the news to hit, you’ll already be too late.March 8, 2025 | Golden Portfolio (Ad)ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Neumora Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - NMRAMarch 7 at 10:58 PM | investing.comLevi & Korsinsky Notifies Neumora Therapeutics, Inc. ...March 7 at 5:05 PM | gurufocus.comJohnson & Johnson axes late-stage program for depression therapyMarch 7 at 4:10 PM | msn.comLevi & Korsinsky Notifies Neumora Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline – NMRAMarch 7 at 2:03 PM | globenewswire.comNeumora cut to Hold at Stifel after J&J’s VENTURA exitMarch 7 at 10:47 AM | msn.comSee More Headlines NMRA Stock Analysis - Frequently Asked Questions How have NMRA shares performed this year? Neumora Therapeutics' stock was trading at $10.60 at the beginning of the year. Since then, NMRA stock has decreased by 85.9% and is now trading at $1.49. View the best growth stocks for 2025 here. How were Neumora Therapeutics' earnings last quarter? Neumora Therapeutics, Inc. (NASDAQ:NMRA) released its quarterly earnings data on Thursday, March, 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.46) by $0.09. When did Neumora Therapeutics IPO? Neumora Therapeutics (NMRA) raised $250 million in an initial public offering (IPO) on Friday, September 15th 2023. The company issued 14,710,000 shares at a price of $17.00 per share. Who are Neumora Therapeutics' major shareholders? Top institutional shareholders of Neumora Therapeutics include Softbank Group CORP. (4.05%), T. Rowe Price Investment Management Inc. (3.10%), Vanguard Group Inc. (2.83%) and Capital International Investors (2.29%). Insiders that own company stock include Amgen Inc, Arch Venture Partners Xii, Llc, Kristina Burow, Robert A Lenz, Joshua Pinto and Michael Lee Milligan. View institutional ownership trends. How do I buy shares of Neumora Therapeutics? Shares of NMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neumora Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neumora Therapeutics investors own include Grayscale Ethereum Trust (ETH) (ETHE), Vale (VALE), Paycom Software (PAYC), Clean Energy Fuels (CLNE), Centrus Energy (LEU), uniQure (QURE) and ThredUp (TDUP). Company Calendar Last Earnings3/06/2025Today3/07/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NMRA CIK1885522 Webneumoratx.com Phone857-760-0900FaxN/AEmployees108Year FoundedN/APrice Target and Rating Average Stock Price Target$10.14 High Stock Price Target$20.00 Low Stock Price Target$2.00 Potential Upside/Downside+580.7%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-235,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-73.63% Return on Assets-68.97% Debt Debt-to-Equity RatioN/A Current Ratio10.98 Quick Ratio10.98 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.07 per share Price / Book0.49Miscellaneous Outstanding Shares161,561,000Free Float118,909,000Market Cap$240.73 million OptionableOptionable Beta2.59 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:NMRA) was last updated on 3/8/2025 by MarketBeat.com Staff From Our PartnersURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | SponsoredBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredDemand For Lithium is only increasing.. .Many analysts are BULLISH, and multibillion dollar industrial conglomerates have invested $30 million in Atlas...Huge Alerts | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.